Proactiveinvestors USA & Canada e-Therapeutics plc https://www.proactiveinvestors.com Proactiveinvestors USA & Canada e-Therapeutics plc RSS feed en Sun, 17 Nov 2019 06:25:11 -0500 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) E-Therapeutics making good progress says chief executive https://www.proactiveinvestors.com/companies/news/904259/e-therapeutics-making-good-progress-says-chief-executive-904259.html Mon, 07 Oct 2019 15:02:00 -0400 https://www.proactiveinvestors.com/companies/news/904259/e-therapeutics-making-good-progress-says-chief-executive-904259.html e-Therapeutics continuing to convert business development into cash generating partnerships https://www.proactiveinvestors.com/companies/news/904275/e-therapeutics-continuing-to-convert-business-development-into-cash-generating-partnerships-904275.html Mon, 07 Oct 2019 11:57:00 -0400 https://www.proactiveinvestors.com/companies/news/904275/e-therapeutics-continuing-to-convert-business-development-into-cash-generating-partnerships-904275.html e-Therapeutics hopeful of securing more collaboration deals in 2019 https://www.proactiveinvestors.com/companies/news/218516/e-therapeutics-hopeful-of-securing-more-collaboration-deals-in-2019-218516.html Mon, 07 Oct 2019 08:40:00 -0400 https://www.proactiveinvestors.com/companies/news/218516/e-therapeutics-hopeful-of-securing-more-collaboration-deals-in-2019-218516.html e-Therapeutics’ Barlow hails deals with Novo Nordisk and ‘top five pharma company’ https://www.proactiveinvestors.com/companies/news/900767/e-therapeutics-barlow-hails-deals-with-novo-nordisk-and-top-five-pharma-company-900767.html Wed, 14 Aug 2019 13:59:00 -0400 https://www.proactiveinvestors.com/companies/news/900767/e-therapeutics-barlow-hails-deals-with-novo-nordisk-and-top-five-pharma-company-900767.html E-Therapeutics signs deal with top five global pharma company for new project https://www.proactiveinvestors.com/companies/news/900610/e-therapeutics-signs-deal-with-top-five-global-pharma-company-for-new-project-900610.html Tue, 13 Aug 2019 07:54:00 -0400 https://www.proactiveinvestors.com/companies/news/900610/e-therapeutics-signs-deal-with-top-five-global-pharma-company-for-new-project-900610.html e-therapeutics teams up with a top-five pharma company for neurodegenerative diseases project https://www.proactiveinvestors.com/companies/news/900599/e-therapeutics-teams-up-with-a-top-five-pharma-company-for-neurodegenerative-diseases-project-900599.html Tue, 13 Aug 2019 06:43:00 -0400 https://www.proactiveinvestors.com/companies/news/900599/e-therapeutics-teams-up-with-a-top-five-pharma-company-for-neurodegenerative-diseases-project-900599.html New tool from e-Therapeutics will analyse genomics of type-2 diabetes patients to find new drugs https://www.proactiveinvestors.com/companies/news/224847/new-tool-from-e-therapeutics-will-analyse-genomics-of-type-2-diabetes-patients-to-find-new-drugs-224847.html Thu, 01 Aug 2019 07:37:00 -0400 https://www.proactiveinvestors.com/companies/news/224847/new-tool-from-e-therapeutics-will-analyse-genomics-of-type-2-diabetes-patients-to-find-new-drugs-224847.html Pharma giant Novo Nordisk extends contract with e-Therapeutics https://www.proactiveinvestors.com/companies/news/314294/pharma-giant-novo-nordisk-extends-contract-with-e-therapeutics-314294.html Thu, 01 Aug 2019 07:12:00 -0400 https://www.proactiveinvestors.com/companies/news/314294/pharma-giant-novo-nordisk-extends-contract-with-e-therapeutics-314294.html e-Therapeutics eyes further partnerships and possibly M&A to fully exploit its potential https://www.proactiveinvestors.com/companies/news/215779/e-therapeutics-eyes-further-partnerships-and-possibly-ma-to-fully-exploit-its-potential-215779.html Tue, 05 Mar 2019 07:33:00 -0500 https://www.proactiveinvestors.com/companies/news/215779/e-therapeutics-eyes-further-partnerships-and-possibly-ma-to-fully-exploit-its-potential-215779.html Danish drugs giant Novo Nordisk to use e-Therapeutics’ technology in search for new diabetes treatments https://www.proactiveinvestors.com/companies/news/210836/danish-drugs-giant-novo-nordisk-to-use-e-therapeutics-technology-in-search-for-new-diabetes-treatments-210836.html Mon, 10 Dec 2018 07:20:00 -0500 https://www.proactiveinvestors.com/companies/news/210836/danish-drugs-giant-novo-nordisk-to-use-e-therapeutics-technology-in-search-for-new-diabetes-treatments-210836.html e-Therapeutics and C4x Discovery team up to find new Parkinson’s treatments https://www.proactiveinvestors.com/companies/news/210641/e-therapeutics-and-c4x-discovery-team-up-to-find-new-parkinsons-treatments-210641.html Thu, 06 Dec 2018 07:46:00 -0500 https://www.proactiveinvestors.com/companies/news/210641/e-therapeutics-and-c4x-discovery-team-up-to-find-new-parkinsons-treatments-210641.html e-therapeutics sees biopharma sector get in tune with its way of thinking https://www.proactiveinvestors.com/companies/news/194210/e-therapeutics-sees-biopharma-sector-get-in-tune-with-its-way-of-thinking-194210.html Mon, 29 Oct 2018 12:43:00 -0400 https://www.proactiveinvestors.com/companies/news/194210/e-therapeutics-sees-biopharma-sector-get-in-tune-with-its-way-of-thinking-194210.html E-therapeutics loss narrows in half year as it files new patent for drug discovery platform https://www.proactiveinvestors.com/companies/news/206358/e-therapeutics-loss-narrows-in-half-year-as-it-files-new-patent-for-drug-discovery-platform-206358.html Thu, 04 Oct 2018 06:45:00 -0400 https://www.proactiveinvestors.com/companies/news/206358/e-therapeutics-loss-narrows-in-half-year-as-it-files-new-patent-for-drug-discovery-platform-206358.html e-Therapeutics and C4X Discovery to collaborate on Parkinson's Disease treatment https://www.proactiveinvestors.com/companies/news/196127/e-therapeutics-and-c4x-discovery-to-collaborate-on-parkinson-s-disease-treatment-196127.html Tue, 01 May 2018 07:45:00 -0400 https://www.proactiveinvestors.com/companies/news/196127/e-therapeutics-and-c4x-discovery-to-collaborate-on-parkinson-s-disease-treatment-196127.html Riccardo Lowi on e-Therapeutics PLC https://www.proactiveinvestors.com/companies/news/330117/riccardo-lowi-on-e-therapeutics-plc-0117.html Wed, 28 Mar 2018 13:47:00 -0400 https://www.proactiveinvestors.com/companies/news/330117/riccardo-lowi-on-e-therapeutics-plc-0117.html e-Therapeutics - FY 2018 Results Show Good Progress https://www.proactiveinvestors.com/companies/news/430597/e-therapeutics---fy-2018-results-show-good-progress-430597.html Wed, 28 Mar 2018 12:02:00 -0400 https://www.proactiveinvestors.com/companies/news/430597/e-therapeutics---fy-2018-results-show-good-progress-430597.html e-therapeutics sees full-year operating loss significantly reduced as turnaround continues under new CEO https://www.proactiveinvestors.com/companies/news/193853/e-therapeutics-sees-full-year-operating-loss-significantly-reduced-as-turnaround-continues-under-new-ceo-193853.html Tue, 27 Mar 2018 07:10:00 -0400 https://www.proactiveinvestors.com/companies/news/193853/e-therapeutics-sees-full-year-operating-loss-significantly-reduced-as-turnaround-continues-under-new-ceo-193853.html e-Therapeutics enhances its AI technology capabilities as it signs two collaboration deals https://www.proactiveinvestors.com/companies/news/190000/e-therapeutics-enhances-its-ai-technology-capabilities-as-it-signs-two-collaboration-deals-190000.html Mon, 15 Jan 2018 07:41:00 -0500 https://www.proactiveinvestors.com/companies/news/190000/e-therapeutics-enhances-its-ai-technology-capabilities-as-it-signs-two-collaboration-deals-190000.html Capital Network's Riccardo Lowi on e-Therapeutics Plc (LON:ETX) https://www.proactiveinvestors.com/companies/news/330083/capital-network-s-riccardo-lowi-on-e-therapeutics-plc-lonetx-0083.html Tue, 31 Oct 2017 09:40:00 -0400 https://www.proactiveinvestors.com/companies/news/330083/capital-network-s-riccardo-lowi-on-e-therapeutics-plc-lonetx-0083.html e-Therapeutics - Capital Network: Undervalued Stock with a Unique Approach to Drug Discovery https://www.proactiveinvestors.com/companies/news/430548/e-therapeutics---capital-network-undervalued-stock-with-a-unique-approach-to-drug-discovery-430548.html Wed, 25 Oct 2017 10:14:00 -0400 https://www.proactiveinvestors.com/companies/news/430548/e-therapeutics---capital-network-undervalued-stock-with-a-unique-approach-to-drug-discovery-430548.html e-Therapeutics sees cash burn and losses fall in first half as new boss’ plans take shape https://www.proactiveinvestors.com/companies/news/184588/e-therapeutics-sees-cash-burn-and-losses-fall-in-first-half-as-new-boss-plans-take-shape-184588.html Tue, 26 Sep 2017 09:01:00 -0400 https://www.proactiveinvestors.com/companies/news/184588/e-therapeutics-sees-cash-burn-and-losses-fall-in-first-half-as-new-boss-plans-take-shape-184588.html e-Therapeutics plc - Elevator Pitch https://www.proactiveinvestors.com/companies/news/307978/e-therapeutics-plc-elevator-pitch-7978.html Tue, 22 Aug 2017 13:57:00 -0400 https://www.proactiveinvestors.com/companies/news/307978/e-therapeutics-plc-elevator-pitch-7978.html e-Therapeutics pioneering the development of improved new drugs with a focus on cancer https://www.proactiveinvestors.com/companies/news/182602/e-therapeutics-pioneering-the-development-of-improved-new-drugs-with-a-focus-on-cancer-182602.html Thu, 17 Aug 2017 09:20:00 -0400 https://www.proactiveinvestors.com/companies/news/182602/e-therapeutics-pioneering-the-development-of-improved-new-drugs-with-a-focus-on-cancer-182602.html e-Therapeutics 'purposefully going out to the world' to engage with big pharma https://www.proactiveinvestors.com/companies/news/307902/e-therapeutics-purposefully-going-out-to-the-world-to-engage-with-big-pharma-7902.html Wed, 09 Aug 2017 07:22:00 -0400 https://www.proactiveinvestors.com/companies/news/307902/e-therapeutics-purposefully-going-out-to-the-world-to-engage-with-big-pharma-7902.html e-Therapeutics unveils results of its strategic review under new chief executive https://www.proactiveinvestors.com/companies/news/181333/e-therapeutics-unveils-results-of-its-strategic-review-under-new-chief-executive-181333.html Mon, 24 Jul 2017 07:54:00 -0400 https://www.proactiveinvestors.com/companies/news/181333/e-therapeutics-unveils-results-of-its-strategic-review-under-new-chief-executive-181333.html It's "Bye, bye, Bilby" as e-Therapeutics and Ultimate Sports join the Bombed Out portfolio https://www.proactiveinvestors.com/companies/news/277907/it-s-bye-bye-bilby-as-e-therapeutics-and-ultimate-sports-join-the-bombed-out-portfolio-27907.html Mon, 05 Jun 2017 15:10:00 -0400 https://www.proactiveinvestors.com/companies/news/277907/it-s-bye-bye-bilby-as-e-therapeutics-and-ultimate-sports-join-the-bombed-out-portfolio-27907.html Drug developer e-Therapeutics streamlines its operation https://www.proactiveinvestors.com/companies/news/176580/drug-developer-e-therapeutics-streamlines-its-operation-176580.html Wed, 19 Apr 2017 07:27:00 -0400 https://www.proactiveinvestors.com/companies/news/176580/drug-developer-e-therapeutics-streamlines-its-operation-176580.html New e-Therapeutics boss 'excited about the future and the steps ahead' https://www.proactiveinvestors.com/companies/news/307257/new-e-therapeutics-boss-excited-about-the-future-and-the-steps-ahead--7257.html Fri, 07 Apr 2017 12:37:00 -0400 https://www.proactiveinvestors.com/companies/news/307257/new-e-therapeutics-boss-excited-about-the-future-and-the-steps-ahead--7257.html First day for new e-Therapeutics boss https://www.proactiveinvestors.com/companies/news/176064/first-day-for-new-e-therapeutics-boss-176064.html Thu, 06 Apr 2017 06:37:00 -0400 https://www.proactiveinvestors.com/companies/news/176064/first-day-for-new-e-therapeutics-boss-176064.html e-Therapeutics appoints Amgen heavy-hitter as new CEO https://www.proactiveinvestors.com/companies/news/171304/e-therapeutics-appoints-amgen-heavy-hitter-as-new-ceo-171304.html Mon, 09 Jan 2017 07:27:00 -0500 https://www.proactiveinvestors.com/companies/news/171304/e-therapeutics-appoints-amgen-heavy-hitter-as-new-ceo-171304.html e-Therapeutics director buys shares with fees https://www.proactiveinvestors.com/companies/news/171138/e-therapeutics-director-buys-shares-with-fees-171138.html Wed, 04 Jan 2017 08:07:00 -0500 https://www.proactiveinvestors.com/companies/news/171138/e-therapeutics-director-buys-shares-with-fees-171138.html e-Therapeutics refocused and well-funded https://www.proactiveinvestors.com/companies/news/166154/e-therapeutics-refocused-and-well-funded-166154.html Tue, 20 Sep 2016 13:57:00 -0400 https://www.proactiveinvestors.com/companies/news/166154/e-therapeutics-refocused-and-well-funded-166154.html Change of focus leads to departure of development director at e-Therapeutics https://www.proactiveinvestors.com/companies/news/165886/change-of-focus-leads-to-departure-of-development-director-at-e-therapeutics-165886.html Wed, 14 Sep 2016 12:26:00 -0400 https://www.proactiveinvestors.com/companies/news/165886/change-of-focus-leads-to-departure-of-development-director-at-e-therapeutics-165886.html E-Therapeutics' chief executive steps down https://www.proactiveinvestors.com/companies/news/128153/e-therapeutics-chief-executive-steps-down-128153.html Wed, 13 Jul 2016 10:39:00 -0400 https://www.proactiveinvestors.com/companies/news/128153/e-therapeutics-chief-executive-steps-down-128153.html e-Therapeutics well-funded and focused on commercialisation https://www.proactiveinvestors.com/companies/news/126359/e-therapeutics-well-funded-and-focused-on-commercialisation-126359.html Wed, 25 May 2016 10:08:00 -0400 https://www.proactiveinvestors.com/companies/news/126359/e-therapeutics-well-funded-and-focused-on-commercialisation-126359.html e-Therapeutics in £2.3mln search engine technology deal https://www.proactiveinvestors.com/companies/news/125784/e-therapeutics-in-23mln-search-engine-technology-deal-125784.html Wed, 11 May 2016 06:45:00 -0400 https://www.proactiveinvestors.com/companies/news/125784/e-therapeutics-in-23mln-search-engine-technology-deal-125784.html e-Therapeutics plc homing in on commercialisation https://www.proactiveinvestors.com/companies/news/123973/e-therapeutics-plc-homing-in-on-commercialisation-123973.html Tue, 22 Mar 2016 14:12:00 -0400 https://www.proactiveinvestors.com/companies/news/123973/e-therapeutics-plc-homing-in-on-commercialisation-123973.html e-Therapeutics plc focused on commercialisation and making alliances https://www.proactiveinvestors.com/companies/news/304807/e-therapeutics-plc-focused-on-commercialisation-and-making-alliances-4807.html Tue, 22 Mar 2016 12:25:00 -0400 https://www.proactiveinvestors.com/companies/news/304807/e-therapeutics-plc-focused-on-commercialisation-and-making-alliances-4807.html e-Therapeutics plc looking for partners as it focuses on discovery platform https://www.proactiveinvestors.com/companies/news/123952/e-therapeutics-plc-looking-for-partners-as-it-focuses-on-discovery-platform-123952.html Tue, 22 Mar 2016 08:25:00 -0400 https://www.proactiveinvestors.com/companies/news/123952/e-therapeutics-plc-looking-for-partners-as-it-focuses-on-discovery-platform-123952.html e-Therapeutics to take more time to assess mixed trial data https://www.proactiveinvestors.com/companies/news/122514/e-therapeutics-to-take-more-time-to-assess-mixed-trial-data-122514.html Mon, 15 Feb 2016 15:55:00 -0500 https://www.proactiveinvestors.com/companies/news/122514/e-therapeutics-to-take-more-time-to-assess-mixed-trial-data-122514.html E-Therapeutics chief says drug candidate has hit a “sweet spot” https://www.proactiveinvestors.com/companies/news/304656/e-therapeutics-chief-says-drug-candidate-has-hit-a-sweet-spot-4656.html Mon, 15 Feb 2016 10:44:00 -0500 https://www.proactiveinvestors.com/companies/news/304656/e-therapeutics-chief-says-drug-candidate-has-hit-a-sweet-spot-4656.html e-Therapeutics hires life sciences veteran as chairman https://www.proactiveinvestors.com/companies/news/121016/e-therapeutics-hires-life-sciences-veteran-as-chairman-121016.html Wed, 06 Jan 2016 09:43:00 -0500 https://www.proactiveinvestors.com/companies/news/121016/e-therapeutics-hires-life-sciences-veteran-as-chairman-121016.html E-Therapeutics welcomes pharma and biotech veteran to board https://www.proactiveinvestors.com/companies/news/116804/e-therapeutics-welcomes-pharma-and-biotech-veteran-to-board-116804.html Thu, 29 Oct 2015 08:04:00 -0400 https://www.proactiveinvestors.com/companies/news/116804/e-therapeutics-welcomes-pharma-and-biotech-veteran-to-board-116804.html E-Therapeutics eyes full control of discovery platform tech https://www.proactiveinvestors.com/companies/news/111241/e-therapeutics-eyes-full-control-of-discovery-platform-tech-111241.html Tue, 29 Sep 2015 08:26:00 -0400 https://www.proactiveinvestors.com/companies/news/111241/e-therapeutics-eyes-full-control-of-discovery-platform-tech-111241.html E-Therapeutics firing on all cylinders https://www.proactiveinvestors.com/companies/news/109999/e-therapeutics-firing-on-all-cylinders-109999.html Mon, 17 Aug 2015 07:06:00 -0400 https://www.proactiveinvestors.com/companies/news/109999/e-therapeutics-firing-on-all-cylinders-109999.html e-Therapeutics bullish on discovery platform https://www.proactiveinvestors.com/companies/news/107937/e-therapeutics-bullish-on-discovery-platform-107937.html Thu, 11 Jun 2015 09:32:00 -0400 https://www.proactiveinvestors.com/companies/news/107937/e-therapeutics-bullish-on-discovery-platform-107937.html e-Therapeutics passes important milestone as first patient is recruited to phase Ib trial https://www.proactiveinvestors.com/companies/news/107069/e-therapeutics-passes-important-milestone-as-first-patient-is-recruited-to-phase-ib-trial-107069.html Thu, 21 May 2015 06:29:00 -0400 https://www.proactiveinvestors.com/companies/news/107069/e-therapeutics-passes-important-milestone-as-first-patient-is-recruited-to-phase-ib-trial-107069.html N+1 Singer upgrades valuation on e-Therapeutics ahead of cancer trials https://www.proactiveinvestors.com/companies/news/67747/n1-singer-upgrades-valuation-on-e-therapeutics-ahead-of-cancer-trials-78968.html Thu, 02 Apr 2015 11:47:00 -0400 https://www.proactiveinvestors.com/companies/news/67747/n1-singer-upgrades-valuation-on-e-therapeutics-ahead-of-cancer-trials-78968.html e-Therapeutics hails 'striking productivity' of drug discovery engine https://www.proactiveinvestors.com/companies/news/67634/e-therapeutics-hails-striking-productivity-of-drug-discovery-engine-78849.html Tue, 31 Mar 2015 07:02:00 -0400 https://www.proactiveinvestors.com/companies/news/67634/e-therapeutics-hails-striking-productivity-of-drug-discovery-engine-78849.html e-Therapeutics shares soar as investors eye discovery pipeline https://www.proactiveinvestors.com/companies/news/66604/e-therapeutics-shares-soar-as-investors-eye-discovery-pipeline-77714.html Thu, 26 Feb 2015 13:43:00 -0500 https://www.proactiveinvestors.com/companies/news/66604/e-therapeutics-shares-soar-as-investors-eye-discovery-pipeline-77714.html e-Therapeutics: Professor Malcolm Young becomes acting chairman https://www.proactiveinvestors.com/companies/news/64976/e-therapeutics-professor-malcolm-young-becomes-acting-chairman-75883.html Mon, 05 Jan 2015 06:56:00 -0500 https://www.proactiveinvestors.com/companies/news/64976/e-therapeutics-professor-malcolm-young-becomes-acting-chairman-75883.html Biotech's hot streak not yet ready to cool https://www.proactiveinvestors.com/companies/news/64850/biotechs-hot-streak-not-yet-ready-to-cool--75748.html The sector is home to some of the stock market’s standout performers over the past year.

]]>
Sat, 27 Dec 2014 13:03:00 -0500 https://www.proactiveinvestors.com/companies/news/64850/biotechs-hot-streak-not-yet-ready-to-cool--75748.html
e-Therapeutics' drug discovery activities rated world class https://www.proactiveinvestors.com/companies/news/64728/e-therapeutics-drug-discovery-activities-rated-world-class-75611.html Fri, 19 Dec 2014 06:44:00 -0500 https://www.proactiveinvestors.com/companies/news/64728/e-therapeutics-drug-discovery-activities-rated-world-class-75611.html e-Therapeutics passes significant milestone as it establishes safe maximum dose for lead drug https://www.proactiveinvestors.com/companies/news/64685/ Thu, 18 Dec 2014 07:45:00 -0500 https://www.proactiveinvestors.com/companies/news/64685/ e-Therapeutics' R&D day takes look at cutting edge new projects https://www.proactiveinvestors.com/companies/news/64007/e-therapeutics-rd-day-takes-look-at-cutting-edge-new-projects-74793.html Thu, 27 Nov 2014 07:07:00 -0500 https://www.proactiveinvestors.com/companies/news/64007/e-therapeutics-rd-day-takes-look-at-cutting-edge-new-projects-74793.html e-Therapeutics' company secretary appointed executive director https://www.proactiveinvestors.com/companies/news/62756/e-therapeutics-company-secretary-appointed-executive-director-73328.html Thu, 16 Oct 2014 10:48:00 -0400 https://www.proactiveinvestors.com/companies/news/62756/e-therapeutics-company-secretary-appointed-executive-director-73328.html e-Therapeutics "in a pretty good place" https://www.proactiveinvestors.com/companies/news/61801/e-therapeutics-in-a-pretty-good-place-72294.html “Our story is quite simple. Development is going full blast; we’ve got four clinical trials going on; and we’ve got plenty of money," CEO Malcolm Young told Proactive Investors.

]]>
Tue, 16 Sep 2014 15:16:00 -0400 https://www.proactiveinvestors.com/companies/news/61801/e-therapeutics-in-a-pretty-good-place-72294.html
e-Therapeutics upbeat on lead drug, discovery platform https://www.proactiveinvestors.com/companies/news/61779/e-therapeutics-upbeat-on-lead-drug-discovery-platform-72269.html Tue, 16 Sep 2014 07:55:00 -0400 https://www.proactiveinvestors.com/companies/news/61779/e-therapeutics-upbeat-on-lead-drug-discovery-platform-72269.html e-Therapeutics finance man buys in https://www.proactiveinvestors.com/companies/news/59717/e-therapeutics-finance-man-buys-in--70093.html Fri, 04 Jul 2014 07:31:00 -0400 https://www.proactiveinvestors.com/companies/news/59717/e-therapeutics-finance-man-buys-in--70093.html e-Therapeutics sees "clear, unobstructed road forward" https://www.proactiveinvestors.com/companies/news/58146/e-therapeutics-sees-clear-unobstructed-road-forward-68417.html Mon, 12 May 2014 07:32:00 -0400 https://www.proactiveinvestors.com/companies/news/58146/e-therapeutics-sees-clear-unobstructed-road-forward-68417.html e-Therapeutics resumes US brain cancer trial recruitment https://www.proactiveinvestors.com/companies/news/58053/e-therapeutics-resumes-us-brain-cancer-trial-recruitment-68319.html Thu, 08 May 2014 06:50:00 -0400 https://www.proactiveinvestors.com/companies/news/58053/e-therapeutics-resumes-us-brain-cancer-trial-recruitment-68319.html E-Therapeutics One2One Investor Presentation April 10th 2014 https://www.proactiveinvestors.com/companies/news/302371/e-therapeutics-one2one-investor-presentation-april-10th-2014-2694.html Fri, 11 Apr 2014 12:42:00 -0400 https://www.proactiveinvestors.com/companies/news/302371/e-therapeutics-one2one-investor-presentation-april-10th-2014-2694.html ETX surges on positive clinical data and appointment of Steve Medlicott https://www.proactiveinvestors.com/companies/news/302364/etx-surges-on-positive-clinical-data-and-appointment-of-steve-medlicott-2364.html Wed, 09 Apr 2014 08:35:00 -0400 https://www.proactiveinvestors.com/companies/news/302364/etx-surges-on-positive-clinical-data-and-appointment-of-steve-medlicott-2364.html UPDATE - e-Therapeutics’ CFO Elger resigns; replaced by Steve Medlicott https://www.proactiveinvestors.com/companies/news/57199/update-e-therapeutics-cfo-elger-resigns-replaced-by-steve-medlicott-67424.html Mon, 07 Apr 2014 13:54:00 -0400 https://www.proactiveinvestors.com/companies/news/57199/update-e-therapeutics-cfo-elger-resigns-replaced-by-steve-medlicott-67424.html ValiRx, e-Therapeutics, Oxford Pharmascience and Action Hotels to present next week https://www.proactiveinvestors.com/companies/news/57152/valirx-e-therapeutics-oxford-pharmascience-and-action-hotels-to-present-next-week-67366.html Next week's Proactive forum promises to be a dynamic evening as it showcases some of the most exciting non-resource companies, which are hot on the market right now.

]]>
Fri, 04 Apr 2014 15:37:00 -0400 https://www.proactiveinvestors.com/companies/news/57152/valirx-e-therapeutics-oxford-pharmascience-and-action-hotels-to-present-next-week-67366.html
UPDATE: e-Therapeutics gets good indications from cancer treatment trial https://www.proactiveinvestors.com/companies/news/56960/update-e-therapeutics-gets-good-indications-from-cancer-treatment-trial-67166.html Treatment was well-tolerated and showed signs of halting tumour progression at higher doses.

]]>
Mon, 31 Mar 2014 12:50:00 -0400 https://www.proactiveinvestors.com/companies/news/56960/update-e-therapeutics-gets-good-indications-from-cancer-treatment-trial-67166.html
e-Therapeutics gets green light to restart UK tumour study https://www.proactiveinvestors.com/companies/news/56822/e-therapeutics-gets-green-light-to-restart-uk-tumour-study-67025.html AIM-listed e-Therapeutics said it has resumed recruiting patients for its early stage trial of drug candidate ETS2101 in solid tumours. The phase 1a study at three centres in the UK was temporarily paused due to a drug storage issue, which has now been resolved.

]]>
Wed, 26 Mar 2014 06:15:00 -0400 https://www.proactiveinvestors.com/companies/news/56822/e-therapeutics-gets-green-light-to-restart-uk-tumour-study-67025.html
e-Therapeutics begins trials on oral version of cancer treatment https://www.proactiveinvestors.com/companies/news/55532/e-therapeutics-begins-trials-on-oral-version-of-cancer-treatment-65652.html e-Therapeutics said it is starting phase-one clinical trials of an oral formulation of its potential cancer treatment ETS2101. It will recruit 24 healthy volunteers who will receive escalating doses of the compound. This will test pharmacokinetics and oral bioavailability.

]]>
Mon, 10 Feb 2014 06:53:00 -0500 https://www.proactiveinvestors.com/companies/news/55532/e-therapeutics-begins-trials-on-oral-version-of-cancer-treatment-65652.html
UPDATE - e-Therapeutics temporarily halts recruitment for cancer drug trial https://www.proactiveinvestors.com/companies/news/55088/update-e-therapeutics-temporarily-halts-recruitment-for-cancer-drug-trial-65158.html Fri, 24 Jan 2014 12:40:00 -0500 https://www.proactiveinvestors.com/companies/news/55088/update-e-therapeutics-temporarily-halts-recruitment-for-cancer-drug-trial-65158.html Q&A: e-Therapeutics' 2014 to be a year of milestones https://www.proactiveinvestors.com/companies/news/54898/qa-e-therapeutics-2014-to-be-a-year-of-milestones-64952.html e-Therapeutics recently updated investors on ETS2101, the drug it’s developing to treat brain cancer. Dr Daniel Elger, the company's chief financial officer, explains the significance of the study.

]]>
Mon, 20 Jan 2014 10:52:00 -0500 https://www.proactiveinvestors.com/companies/news/54898/qa-e-therapeutics-2014-to-be-a-year-of-milestones-64952.html
e-Therapeutics brain cancer drug trial to enrol further patients https://www.proactiveinvestors.com/companies/news/54551/e-therapeutics-brain-cancer-drug-trial-to-enrol-further-patients-64593.html Drug discovery group e-Therapeutics said there had been no serious drug related side effects from ETS20101, which is being developed to treat brain cancer. The compound is currently in phase I where the aim is to assess safety and tolerability.

]]>
Tue, 07 Jan 2014 06:31:00 -0500 https://www.proactiveinvestors.com/companies/news/54551/e-therapeutics-brain-cancer-drug-trial-to-enrol-further-patients-64593.html
e-Therapeutics starts Phase IIb drug trial https://www.proactiveinvestors.com/companies/news/52834/-e-therapeutics-starts-phase-iib-drug-trial-62746.html Thu, 31 Oct 2013 06:56:00 -0400 https://www.proactiveinvestors.com/companies/news/52834/-e-therapeutics-starts-phase-iib-drug-trial-62746.html e-Therapeutics positioned to progress drugs in clinical pipeline, says Edison https://www.proactiveinvestors.com/companies/news/52593/e-therapeutics-positioned-to-progress-drugs-in-clinical-pipeline-says-edison-62469.html Wed, 23 Oct 2013 16:23:00 -0400 https://www.proactiveinvestors.com/companies/news/52593/e-therapeutics-positioned-to-progress-drugs-in-clinical-pipeline-says-edison-62469.html e-Therapeutics' cash to last longer than anticipated, says CFO https://www.proactiveinvestors.com/companies/news/52383/e-therapeutics-cash-to-last-longer-than-anticipated-says-cfo-62215.html e-Therapeutics expects the £45mln it has on the balance sheet to last it until 2018, a year longer than first anticipated, according to chief financial officer Daniel Elger.

]]>
Wed, 16 Oct 2013 14:47:00 -0400 https://www.proactiveinvestors.com/companies/news/52383/e-therapeutics-cash-to-last-longer-than-anticipated-says-cfo-62215.html
UPDATE - e-Therapeutics' cash management a pleasant surprise to Panmure Gordon https://www.proactiveinvestors.com/companies/news/52366/update-e-therapeutics-cash-management-a-pleasant-surprise-to-panmure-gordon-62198.html e-Therapeutics revealed its lead drug is making steady progress through the early stages of the clinical trial process as it updated on its own financial health.

]]>
Wed, 16 Oct 2013 12:09:00 -0400 https://www.proactiveinvestors.com/companies/news/52366/update-e-therapeutics-cash-management-a-pleasant-surprise-to-panmure-gordon-62198.html
Showcasing Britain's Talent- Proactive One2One forums come to London & Manchester https://www.proactiveinvestors.com/companies/news/48891/showcasing-britains-talent-proactive-one2one-forums-come-to-london-manchester-58261.html ‘London to Manchester’ sounds like the title to a biography of footballer Robin van Persie, but is, in fact, a description of Proactive Investors’ exciting events schedule in the final week of June.

]]>
Fri, 21 Jun 2013 17:50:00 -0400 https://www.proactiveinvestors.com/companies/news/48891/showcasing-britains-talent-proactive-one2one-forums-come-to-london-manchester-58261.html
e-Therapeutics provides a clear road-map to value creation https://www.proactiveinvestors.com/companies/news/47817/e-therapeutics-provides-a-clear-road-map-to-value-creation--56992.html The struggle for any ambitious biopharma group is finding sufficient cash to take a breakthrough treatment to the point where it maximises value for the company and its investors. For e-Therapeutics, the funding silver bullet was fired in March when it successfully concluded a £40mln cash call

]]>
Thu, 16 May 2013 13:11:00 -0400 https://www.proactiveinvestors.com/companies/news/47817/e-therapeutics-provides-a-clear-road-map-to-value-creation--56992.html
e-Therapeutics mulling next development candidate https://www.proactiveinvestors.com/companies/news/47784/e-therapeutics-mulling-next-development-candidate-56945.html  

e-Therapeutics (LON:ETX) is making encouraging progress on its existing drugs candidates but with a healthy cash position, it is already looking at adding to its development portfolio.

Shares shot up on Tuesday after the group revealed encouraging news from the phase I trial of its lead drug, ETS2101.

 

]]>
Wed, 15 May 2013 14:13:00 -0400 https://www.proactiveinvestors.com/companies/news/47784/e-therapeutics-mulling-next-development-candidate-56945.html
UPDATE - e-Therapeutics surges on phase I progress for lead candidate https://www.proactiveinvestors.com/companies/news/47706/update-e-therapeutics-surges-on-phase-i-progress-for-lead-candidate-56859.html Cash rich drug developer e-Therapeutics is gaining momentum with the first findings from its phase I programme of its lead cancer drug, ETS2101, coming through, while its anti-depressant drug, ETS6103, is lined up for a phase IIb trial.

]]>
Tue, 14 May 2013 11:32:00 -0400 https://www.proactiveinvestors.com/companies/news/47706/update-e-therapeutics-surges-on-phase-i-progress-for-lead-candidate-56859.html
e-Therapeutics completes placings to raise £40mln https://www.proactiveinvestors.com/companies/news/45507/e-therapeutics-completes-placings-to-raise-40mln-54295.html Fri, 01 Mar 2013 08:22:00 -0500 https://www.proactiveinvestors.com/companies/news/45507/e-therapeutics-completes-placings-to-raise-40mln-54295.html UPDATE: e-Therapeutics rises after investors back fund raising https://www.proactiveinvestors.com/companies/news/44880/update-e-therapeutics-rises-after-investors-back-fund-raising-53545.html Drug discovery and development company e-Therapeutics (LON:ETX) is to raise £40 million through a placing of shares with existing and new institutional shareholders. Broker Panmure Gordon described the placing as a “significant recapitalisation”.

]]>
Mon, 11 Feb 2013 15:14:00 -0500 https://www.proactiveinvestors.com/companies/news/44880/update-e-therapeutics-rises-after-investors-back-fund-raising-53545.html
e-Therapeutics places shares at a premium https://www.proactiveinvestors.com/companies/news/44843/e-therapeutics-places-shares-at-a-premium-53503.html Dr Daniel Elger, Chief Financial Officer of e-Therapeutics, said: “This fundraising provides us with the resources needed for significant investment in new drug discovery and to take our lead cancer drug ETS2101 through efficacy-focused trials that could lead to a lucrative licensing deal.”

]]>
Mon, 11 Feb 2013 06:14:00 -0500 https://www.proactiveinvestors.com/companies/news/44843/e-therapeutics-places-shares-at-a-premium-53503.html
UPDATE: e-Therapeutics' early data encourages https://www.proactiveinvestors.com/companies/news/43304/update-e-therapeutics-early-data-encourages-51668.html Early and very limited results from e-Therapeutics’ (LON:EXT) phase I trial of cancer drug candidate ETS2101 have so far revealed no “dose limiting toxicities” or other adverse effects.

]]>
Tue, 18 Dec 2012 14:09:00 -0500 https://www.proactiveinvestors.com/companies/news/43304/update-e-therapeutics-early-data-encourages-51668.html
e-Therapeutics early data encourages https://www.proactiveinvestors.com/companies/news/43289/e-therapeutics-early-data-encourages--51651.html Early and very limited results from e-Therapeutics’ phase I trial of cancer drug candidate ETS2101 have so far revealed no “dose limiting toxicities” or other adverse effects. So far, 12 patients have been given low doses of the treatment in phase I studies, which are designed to test the safety and tolerability. The amount administered will be increased over time.

]]>
Tue, 18 Dec 2012 06:53:00 -0500 https://www.proactiveinvestors.com/companies/news/43289/e-therapeutics-early-data-encourages--51651.html
e-Therapeutics funded to deliver ‘significant milestones’ https://www.proactiveinvestors.com/companies/news/41461/e-therapeutics-funded-to-deliver-significant-milestones-49440.html The drug developer's working capital will see it funded not only through the phase I data for its key cancer drug, but also beyond when it expects to get the data from its phase II b trial on depression in the second quarter of 2014.

]]>
Mon, 22 Oct 2012 16:30:00 -0400 https://www.proactiveinvestors.com/companies/news/41461/e-therapeutics-funded-to-deliver-significant-milestones-49440.html
E-Therapeutics chief Young looks forward to major clinical milestones https://www.proactiveinvestors.com/companies/news/41441/e-therapeutics-chief-young-looks-forward-to-major-clinical-milestones-49418.html E-Therapeutics chief Dr Malcolm Young today said he is looking forward to some major clinical milestones after a year of significant progress.

]]>
Mon, 22 Oct 2012 09:11:00 -0400 https://www.proactiveinvestors.com/companies/news/41441/e-therapeutics-chief-young-looks-forward-to-major-clinical-milestones-49418.html
e-Therapeutics is growing momentum, says GECR https://www.proactiveinvestors.com/companies/news/40559/e-therapeutics-is-growing-momentum-says-gecr-48363.html Mon, 24 Sep 2012 16:43:00 -0400 https://www.proactiveinvestors.com/companies/news/40559/e-therapeutics-is-growing-momentum-says-gecr-48363.html e-Therapeutics launches second phase I anti-cancer drug trial https://www.proactiveinvestors.com/companies/news/40221/e-therapeutics-launches-second-phase-i-anti-cancer-drug-trial-47988.html Wed, 12 Sep 2012 06:41:00 -0400 https://www.proactiveinvestors.com/companies/news/40221/e-therapeutics-launches-second-phase-i-anti-cancer-drug-trial-47988.html UPDATE: e-Therapeutics cancer drug enters US phase I trials https://www.proactiveinvestors.com/companies/news/37083/update-e-therapeutics-cancer-drug-enters-us-phase-i-trials-44346.html Tue, 19 Jun 2012 14:14:00 -0400 https://www.proactiveinvestors.com/companies/news/37083/update-e-therapeutics-cancer-drug-enters-us-phase-i-trials-44346.html e-Therapeutics cancer drug enters US phase I trials https://www.proactiveinvestors.com/companies/news/37069/e-therapeutics-cancer-drug-enters-us-phase-i-trials-44326.html Tue, 19 Jun 2012 06:50:00 -0400 https://www.proactiveinvestors.com/companies/news/37069/e-therapeutics-cancer-drug-enters-us-phase-i-trials-44326.html e-Therapeutics has laid the foundations for a transformational 18 months https://www.proactiveinvestors.com/companies/news/36670/e-therapeutics-has-laid-the-foundations-for-a-transformational-18-months-43846.html The official opening of its new Oxford drug discovery centre by Prime Minister David Cameron has set the scene for what could be a landmark 12 to 18 months for e-Therapeutics. 

]]>
Thu, 07 Jun 2012 10:06:00 -0400 https://www.proactiveinvestors.com/companies/news/36670/e-therapeutics-has-laid-the-foundations-for-a-transformational-18-months-43846.html
Mellon examines biotech industry in UK and US - Pt 3 https://www.proactiveinvestors.com/companies/news/36532/mellon-examines-biotech-industry-in-uk-and-us-pt-3-43674.html Here, in the third and final installment, Jim Mellon discusses the state of the industry, both here and in the US, and the drivers.

 

]]>
Tue, 05 Jun 2012 09:00:00 -0400 https://www.proactiveinvestors.com/companies/news/36532/mellon-examines-biotech-industry-in-uk-and-us-pt-3-43674.html
e-Therapeutics expects first data from new drug trials this year - UPDATE https://www.proactiveinvestors.com/companies/news/36107/e-therapeutics-expects-first-data-from-new-drug-trials-this-year-update-43150.html Drug discovery and development company e-Therapeutics expects to see the first findings from its new programme of clinical trials before the end of this year.

]]>
Tue, 22 May 2012 13:32:00 -0400 https://www.proactiveinvestors.com/companies/news/36107/e-therapeutics-expects-first-data-from-new-drug-trials-this-year-update-43150.html
e-Therapeutics expects first data from new drug trials before yr-end https://www.proactiveinvestors.com/companies/news/36072/e-therapeutics-expects-first-data-from-new-drug-trials-before-yr-end-43115.html Tue, 22 May 2012 06:25:00 -0400 https://www.proactiveinvestors.com/companies/news/36072/e-therapeutics-expects-first-data-from-new-drug-trials-before-yr-end-43115.html e-Therapeutics gets regulators’ nod for phase I clinical trials of cancer drug ETS2101 https://www.proactiveinvestors.com/companies/news/34306/e-therapeutics-gets-regulators-nod-for-phase-i-clinical-trials-of-cancer-drug-ets2101-40890.html Thu, 29 Mar 2012 08:04:00 -0400 https://www.proactiveinvestors.com/companies/news/34306/e-therapeutics-gets-regulators-nod-for-phase-i-clinical-trials-of-cancer-drug-ets2101-40890.html e-Therapeutics: David Cameron opens firm's new centre https://www.proactiveinvestors.com/companies/news/33111/e-therapeutics-david-cameron-opens-firms-new-centre-39436.html Mon, 27 Feb 2012 06:27:00 -0500 https://www.proactiveinvestors.com/companies/news/33111/e-therapeutics-david-cameron-opens-firms-new-centre-39436.html e-Therapeutics bolsters board ahead of clinical trials https://www.proactiveinvestors.com/companies/news/32441/e-therapeutics-bolsters-board-ahead-of-clinical-trials-38631.html Mon, 06 Feb 2012 07:54:00 -0500 https://www.proactiveinvestors.com/companies/news/32441/e-therapeutics-bolsters-board-ahead-of-clinical-trials-38631.html e-Therapeutics says four drugs will enter clinical trials this year https://www.proactiveinvestors.com/companies/news/31467/e-therapeutics-says-four-drugs-will-enter-clinical-trials-this-year-37603.html Mon, 09 Jan 2012 13:52:00 -0500 https://www.proactiveinvestors.com/companies/news/31467/e-therapeutics-says-four-drugs-will-enter-clinical-trials-this-year-37603.html e-Therapeutics' accelerated growth strategy remains on track, says GECR https://www.proactiveinvestors.com/companies/news/29052/e-therapeutics-accelerated-growth-strategy-remains-on-track-says-gecr-34721.html Mon, 24 Oct 2011 13:36:00 -0400 https://www.proactiveinvestors.com/companies/news/29052/e-therapeutics-accelerated-growth-strategy-remains-on-track-says-gecr-34721.html e-Therapeutics: 2012 represents key year for the business https://www.proactiveinvestors.com/companies/news/28919/e-therapeutics-2012-represents-key-year-for-the-business-34565.html The firm is looking to generate a flow of data from four drugs that it is putting through Phase I and Phase II trials next year and in 2013

]]>
Wed, 19 Oct 2011 15:16:00 -0400 https://www.proactiveinvestors.com/companies/news/28919/e-therapeutics-2012-represents-key-year-for-the-business-34565.html
e-Therapeutics looks forward to 2012 https://www.proactiveinvestors.com/companies/news/28900/e-therapeutics-looks-forward-to-2012-34541.html Wed, 19 Oct 2011 07:29:00 -0400 https://www.proactiveinvestors.com/companies/news/28900/e-therapeutics-looks-forward-to-2012-34541.html E-Therapeutics has 'buy' rating reiterated by Panmure ahead of interims https://www.proactiveinvestors.com/companies/news/28875/e-therapeutics-has-buy-rating-reiterated-by-panmure-ahead-of-interims--34503.html Tue, 18 Oct 2011 14:27:00 -0400 https://www.proactiveinvestors.com/companies/news/28875/e-therapeutics-has-buy-rating-reiterated-by-panmure-ahead-of-interims--34503.html e-Therapeutics granted US patent for key process https://www.proactiveinvestors.com/companies/news/28088/e-therapeutics-granted-us-patent-for-key-process-33558.html Mon, 26 Sep 2011 07:33:00 -0400 https://www.proactiveinvestors.com/companies/news/28088/e-therapeutics-granted-us-patent-for-key-process-33558.html e-Therapeutics: “significant room for upside” https://www.proactiveinvestors.com/companies/news/26285/e-therapeutics-significant-room-for-upside-31364.html Mon, 01 Aug 2011 11:52:00 -0400 https://www.proactiveinvestors.com/companies/news/26285/e-therapeutics-significant-room-for-upside-31364.html e-Therapeutics' chief financial officer buys stake in firm https://www.proactiveinvestors.com/companies/news/26172/e-therapeutics-chief-financial-officer-buys-stake-in-firm-31240.html

]]>
Thu, 28 Jul 2011 08:08:00 -0400 https://www.proactiveinvestors.com/companies/news/26172/e-therapeutics-chief-financial-officer-buys-stake-in-firm-31240.html
E-Therapeutics platform technology the main reason to invest in the stock, says Panmure's Neophytou https://www.proactiveinvestors.com/companies/news/26073/e-therapeutics-platform-technology-the-main-reason-to-invest-in-the-stock-says-panmures-neophytou-31117.html City broker Panmure Gordon this morning repeated its buy recommendation on e-Therapuetics after the prelims yesterday, although tweaked its price target down a little.

]]>
Tue, 26 Jul 2011 10:49:00 -0400 https://www.proactiveinvestors.com/companies/news/26073/e-therapeutics-platform-technology-the-main-reason-to-invest-in-the-stock-says-panmures-neophytou-31117.html
E-Therapeutics chief executive excited by potential of cancer drug https://www.proactiveinvestors.com/companies/news/26031/e-therapeutics-chief-executive-excited-by-potential-of-cancer-drug-31073.html Professor Malcolm Young today spoke of his hopes for the cancer treatment being developed by e-Therapeutics as part of full-funded programme to unlock the potential of four drug candidates.

]]>
Mon, 25 Jul 2011 12:13:00 -0400 https://www.proactiveinvestors.com/companies/news/26031/e-therapeutics-chief-executive-excited-by-potential-of-cancer-drug-31073.html
E-Therapeutics expects to generate a "wealth of data" from clinical trials https://www.proactiveinvestors.com/companies/news/26010/e-therapeutics-expects-to-generate-a-wealth-of-data-from-clinical-trials-31051.html

E-Therapeutics expects to generate a “wealth of data” from a clinical programme focusing on four drug candidates. This pipeline was identified using a platform called network pharmacology and spans cancer, infections and psychiatry.

]]>
Mon, 25 Jul 2011 06:51:00 -0400 https://www.proactiveinvestors.com/companies/news/26010/e-therapeutics-expects-to-generate-a-wealth-of-data-from-clinical-trials-31051.html
e-Therapeutics names Daniel Elger new chief financial officer https://www.proactiveinvestors.com/companies/news/24530/e-therapeutics-names-daniel-elger-new-chief-financial-officer-29306.html Mon, 13 Jun 2011 07:54:00 -0400 https://www.proactiveinvestors.com/companies/news/24530/e-therapeutics-names-daniel-elger-new-chief-financial-officer-29306.html e-Therapeutics seeks new drug candidates and collaborations - Edison https://www.proactiveinvestors.com/companies/news/23468/e-therapeutics-seeks-new-drug-candidates-and-collaborations-edison-28021.html Mon, 09 May 2011 14:05:00 -0400 https://www.proactiveinvestors.com/companies/news/23468/e-therapeutics-seeks-new-drug-candidates-and-collaborations-edison-28021.html e-Therapeutics Audio Interview Transcript with Malcolm Young, CEO https://www.proactiveinvestors.com/companies/news/22272/e-therapeutics-audio-interview-transcript-with-malcolm-young-ceo-26582.html Tue, 22 Mar 2011 13:52:00 -0400 https://www.proactiveinvestors.com/companies/news/22272/e-therapeutics-audio-interview-transcript-with-malcolm-young-ceo-26582.html e-Therapeutics executive director Steve Self ups holding https://www.proactiveinvestors.com/companies/news/22113/e-therapeutics-executive-director-steve-self-ups-holding-26376.html Tue, 15 Mar 2011 14:03:00 -0400 https://www.proactiveinvestors.com/companies/news/22113/e-therapeutics-executive-director-steve-self-ups-holding-26376.html e-Therapeutics executive director Steve Self buys more shares https://www.proactiveinvestors.com/companies/news/22084/e-therapeutics-executive-director-steve-self-buys-more-shares-26347.html Mon, 14 Mar 2011 14:46:00 -0400 https://www.proactiveinvestors.com/companies/news/22084/e-therapeutics-executive-director-steve-self-buys-more-shares-26347.html e-Therapeutics executive director Steve Self ups stake https://www.proactiveinvestors.com/companies/news/21877/e-therapeutics-executive-director-steve-self-ups-stake-26093.html Fri, 04 Mar 2011 09:11:00 -0500 https://www.proactiveinvestors.com/companies/news/21877/e-therapeutics-executive-director-steve-self-ups-stake-26093.html e-Therapeutics development director Steve Self buys shares in company https://www.proactiveinvestors.com/companies/news/21818/-e-therapeutics-development-director-steve-self-buys-shares-in-company-26013.html Wed, 02 Mar 2011 09:49:00 -0500 https://www.proactiveinvestors.com/companies/news/21818/-e-therapeutics-development-director-steve-self-buys-shares-in-company-26013.html e-Therapeutics CEO Young 'stunned' by strong backing for cash call https://www.proactiveinvestors.com/companies/news/21425/e-therapeutics-ceo-young-stunned-by-strong-backing-for-cash-call-25543.html The Newcastle-based drug developer had been expected to come to the market for £4-5 million. Instead it is raising £17.6 million from six big investors, which will help it develop four drug candidates. In an interview, CEO Malcolm Young tells Proactive Investors how surprised he was: "Everybody we approached was saying yes."

]]>
Tue, 15 Feb 2011 11:30:00 -0500 https://www.proactiveinvestors.com/companies/news/21425/e-therapeutics-ceo-young-stunned-by-strong-backing-for-cash-call-25543.html
E-Therapeutics raises £17.6 mln to develop four lead drug candidates https://www.proactiveinvestors.com/companies/news/21415/e-therapeutics-raises-176-mln-to-develop-four-lead-drug-candidates-25524.html E-Therapeutics surprised the market today with a £17.6 million placing that will alleviate worries over its funding needs. The amount raised is far higher than most analysts envisaged, but allows the company to simultaneously develop four of its most promising drug candidates whilst carry on talks with potential collaboration partners. The cash injection of course puts the company in a far stronger bargaining position. 

]]>
Tue, 15 Feb 2011 07:02:00 -0500 https://www.proactiveinvestors.com/companies/news/21415/e-therapeutics-raises-176-mln-to-develop-four-lead-drug-candidates-25524.html
e-Therapeutics promotes development director Steve Self to the board https://www.proactiveinvestors.com/companies/news/19851/e-therapeutics-promotes-development-director-steve-self-to-the-board-23690.html Mon, 06 Dec 2010 07:39:00 -0500 https://www.proactiveinvestors.com/companies/news/19851/e-therapeutics-promotes-development-director-steve-self-to-the-board-23690.html e-Therapeutics exploring its funding options as three drug candidates go into phase II trials https://www.proactiveinvestors.com/companies/news/18850/e-therapeutics-exploring-its-funding-options-as-three-drug-candidates-go-into-phase-ii-trials-22541.html Fri, 29 Oct 2010 07:14:00 -0400 https://www.proactiveinvestors.com/companies/news/18850/e-therapeutics-exploring-its-funding-options-as-three-drug-candidates-go-into-phase-ii-trials-22541.html E-Therapeutics, Advanced Cell Technology, Kiotech & Camco at the next Proactive forum https://www.proactiveinvestors.com/companies/news/18370/e-therapeutics-advanced-cell-technology-kiotech-camco-at-the-next-proactive-forum-21975.html We have an exciting line-up for our latest investor forum at the Mayfair Chesterfield Hotel on Thursday. Come along and see e-Therapeutics, Advanced Cell Technology, Kiotech and Camco. Oh, and read just what happened after our last non-resources event.

]]>
Tue, 12 Oct 2010 09:06:00 -0400 https://www.proactiveinvestors.com/companies/news/18370/e-therapeutics-advanced-cell-technology-kiotech-camco-at-the-next-proactive-forum-21975.html
e-Therapeutics entering a decisive phase in its development https://www.proactiveinvestors.com/companies/news/18247/e-therapeutics-entering-a-decisive-phase-in-its-development--21837.html We speak to Professor Malcolm Young and Jonny Cordiner of e-Therapeutics about network pharmacology, which could revolutionise the way medicines are developed. And we look at products the company is developing using the science.

]]>
Fri, 08 Oct 2010 06:12:00 -0400 https://www.proactiveinvestors.com/companies/news/18247/e-therapeutics-entering-a-decisive-phase-in-its-development--21837.html
Panmure Gordon sees e-Therapeutics nearly tripling share value https://www.proactiveinvestors.com/companies/news/18131/panmure-gordon-sees-e-therapeutics-nearly-tripling-share-value-21699.html Mon, 04 Oct 2010 11:01:00 -0400 https://www.proactiveinvestors.com/companies/news/18131/panmure-gordon-sees-e-therapeutics-nearly-tripling-share-value-21699.html e-Therapeutics wins further wide-ranging patent in the US https://www.proactiveinvestors.com/companies/news/17730/e-therapeutics-wins-further-wide-ranging-patent-in-the-us-21250.html Wed, 22 Sep 2010 06:52:00 -0400 https://www.proactiveinvestors.com/companies/news/17730/e-therapeutics-wins-further-wide-ranging-patent-in-the-us-21250.html e-Therapeutics reports 'another successful year' as a streamlined and strengthened drug-developer https://www.proactiveinvestors.com/companies/news/15061/e-therapeutics-reports-another-successful-year-as-a-streamlined-and-strengthened-drug-developer-18253.html Tue, 29 Jun 2010 11:13:00 -0400 https://www.proactiveinvestors.com/companies/news/15061/e-therapeutics-reports-another-successful-year-as-a-streamlined-and-strengthened-drug-developer-18253.html